Samaritan Moves Development of Caprospinol Ahead Through Advinus Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The company plans to run extensive preclinical studies evaluating the Alzheimer’s candidate, then enter Phase I trials by the end of the year.
You may also be interested in...
Genentech To Acquire AC Immune’s Beta-Amyloid Antibodies For Alzheimer’s Research
The biotech will pay more than $300 million for preclinical conformation-specific antibodies against beta-amyloid.
Elan Moving Alzheimer’s Candidate To Phase II Under Pact With Transition Therapeutics
Initial terms of the partnership include an unusual 70/30 split on development costs and eventual profits.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.